Litcius/Paper detail

Persistent maculopapular rash after the first dose of Pfizer‐BioNTech COVID‐19 vaccine

Marianela Ackerman, D. Henry, A. Finon, R. Binois, É. Estève

2021Journal of the European Academy of Dermatology and Venereology46 citationsDOIOpen Access PDF

Abstract

developed such lesion. This could be explained by the fact that we did not include paediatric patients, where pernio commonly manifests. 1 Retiform purpura and skin necrosis are cutaneous manifestations that correlate strongly with severe COVID-19 infection; the Spanish Workgroup that studied 375 patients reported that individuals who developed these cutaneous manifestations have a mortality of 10%. 1,2 Results obtained from our study are similar to what is reported in literature. In the database collected by the AAD, manifestations considered to be related with a favourable-intermediate prognosis were pernio, morbilliform exanthem, urticaria, macular erythema, vesicular eruption and papulosquamous eruption.

Topics & Concepts

Maculopapular rashMedicineRashSurgerySARS-CoV-2 and COVID-19 ResearchDrug-Induced Adverse ReactionsDermatological and COVID-19 studies
Persistent maculopapular rash after the first dose of Pfizer‐BioNTech COVID‐19 vaccine | Litcius